Log In
Print
BCIQ
Print
Print this Print this
 

SMC-103

  Manage Alerts
Collapse Summary General Information
Company SMC Biotechnology Inc.
DescriptionGlycosaminoglycan (GAG) that enhances the pro-healing effects of endogenously produced bone morphogenetic protein 2 (BMP2)
Molecular Target Bone morphogenetic protein 2 (BMP2)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationBone repair
Indication DetailsEnhance bone repair; Promote long bone healing and spinal fusion as an alternative to bone graft and bone graft substitutes
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today